These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4087037)

  • 1. Polyribonucleotides for cancer therapy: summary and recommendations for further research.
    Herberman RB; Pinsky CM
    J Biol Response Mod; 1985 Dec; 4(6):680-4. PubMed ID: 4087037
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer.
    Theriault RL; Hortobagyi GN; Buzdar AU; Levy HB; Hersh EM
    Cancer Treat Rep; 1986 Nov; 70(11):1341-2. PubMed ID: 3768878
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase I evaluation of poly(I,C)-LC in cancer patients.
    Stevenson HC; Abrams PG; Schoenberger CS; Smalley RB; Herberman RB; Foon KA
    J Biol Response Mod; 1985 Dec; 4(6):650-5. PubMed ID: 2418163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of interferon and poly ICLC, and their possible utility as anti-neoplastic agents in man.
    Levy HB; Levine AS
    Tex Rep Biol Med; 1981-1982; 41():653-62. PubMed ID: 6189230
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferons and interferon inducers in cancer treatment.
    Krown SE
    Semin Oncol; 1986 Jun; 13(2):207-17. PubMed ID: 2424089
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I trials of poly(I,C) complexes in advanced cancer.
    Krown SE; Kerr D; Stewart WE; Field AK; Oettgen HF
    J Biol Response Mod; 1985 Dec; 4(6):640-9. PubMed ID: 2418162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trials of biological response modifiers.
    Smalley RV; Oldham RK
    Drugs Exp Clin Res; 1986; 12(1-3):31-9. PubMed ID: 3089752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC)).
    Rettenmaier MA; Berman ML; DiSaia PJ
    Gynecol Oncol; 1986 Jul; 24(3):359-61. PubMed ID: 3721308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of interferon on rabies infection of animals.
    Baer GM
    Tex Rep Biol Med; 1981-1982; 41():526-31. PubMed ID: 6189218
    [No Abstract]   [Full Text] [Related]  

  • 10. Liver enzyme abnormalities after poly ICLC infusions.
    Hess WA; Bever CT; McFarlin DE
    Cancer Treat Rep; 1985 Nov; 69(11):1342. PubMed ID: 2418967
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential role of polyribonucleotides in human neoplastic diseases.
    Borden EC; Verma AK; Wolberg WH
    J Biol Response Mod; 1985 Dec; 4(6):676-9. PubMed ID: 4087036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor effect of Corynebacterium parvum and poly ICLC on experimental brain tumors].
    Kiya K; Kitaoka T; Okamoto H; Harada K; Uozumi T; Toge T; Hattori T; Machida H
    Neurol Med Chir (Tokyo); 1983 Nov; 23(11):841-8. PubMed ID: 6201759
    [No Abstract]   [Full Text] [Related]  

  • 13. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.
    Hawkins MJ; Levin M; Borden EC
    J Biol Response Mod; 1985 Dec; 4(6):664-8. PubMed ID: 2418164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon induction and therapy of brain tumors in rats by poly(ICLC).
    Machida H; Takezawa J; Kuninaka A; Yoshino H; Nakamura O; Takakura K
    Microbiol Immunol; 1982; 26(4):353-8. PubMed ID: 6180284
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of recurrent laryngeal papillomatosis with an artificial interferon inducer (poly ICLC).
    Leventhal BG; Kashima H; Levine AS; Levy HB
    J Pediatr; 1981 Oct; 99(4):614-6. PubMed ID: 7277106
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunomodulatory effects of poly(I,C)-LC in cancer patients.
    Maluish AE; Reid JW; Crisp EA; Overton WR; Levy H; Foon KA; Herberman RB
    J Biol Response Mod; 1985 Dec; 4(6):656-63. PubMed ID: 4087034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.
    Talmadge JE; Chirigos MA
    Springer Semin Immunopathol; 1985; 8(4):429-43. PubMed ID: 3879016
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
    Kende M
    J Biol Response Mod; 1985 Oct; 4(5):503-11. PubMed ID: 2416883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].
    Chirigos MA; Schlick E; Ruffmann R; Budzynski W; Sinibaldi P; Gruys E
    J Biol Response Mod; 1985 Dec; 4(6):621-7. PubMed ID: 4087033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.